Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Sponsor: NRG Oncology
This observational or N/A phase trial investigates Fallopian Tube High Grade Serous Adenocarcinoma and Ovarian High Grade Serous Adenocarcinoma and is currently ongoing. NRG Oncology leads this study, which shows 80 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)PRIMARY OBJECTIVES: I. Estimate the probability of a dose limiting toxicity (DLT) following cycle 1 of experimental regimens (pegylated liposomal doxorubicin hydrochloride \[pegylated liposomal doxorubicin\] \[PLD\] and atezolizumab and PLD/bevacizumab and atezolizumab). (Safety lead-in) II. Estimate and compare the hazard of first progression or death (progression free survival \[PFS\]) of each experimental regimen relative to the reference regimen, PLD and bevacizumab. (Phase II study) III. Estimate and compare the hazard of death and the hazard of first progression or death (PFS) of the experimental regimen relative to the reference regimen. (Phase III) (24-FEB-2021) SECONDARY OBJECTIVES: I. Estimate and compare the probabilities of response (objective response rate \[ORR\], either partial or complete response) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria on each study regimen. (Phase II study) (24-FEB-2021) II. Estimate the frequency and severity of adverse events as classified and graded with Common Terminology Criteria for Adverse Events (CTCAE) in those patients who initiate their randomly assigned study treatment. (Phase II study) (03/19/2018) III. Estimate and compare ORR in each treatment group. (Phase III study) IV. Estimate the frequency and severity of adverse events in those patients who initiate their randomly assigned study treatment. (Phase III...
PRIMARY OBJECTIVES:
I. Estimate the probability of a dose limiting toxicity (DLT) following cycle 1 of experimental regimens (pegylated liposomal doxorubicin hydrochloride \[pegylated liposomal doxorubicin\] \[PLD\] and atezolizumab and PLD/bevacizumab and atezolizumab). (Safety lead-in) II. Estimate and compare the hazard of first progression or death (progression free survival \[PFS\]) of each experimental regimen relative to the reference regimen, PLD and bevacizumab. (Phase II study) III. Estimate and compare the hazard of death and the hazard of first progression or death (PFS) of the experimental regimen relative to the reference regimen. (Phase III) (24-FEB-2021)
SECONDARY OBJECTIVES:
I. Estimate and compare the probabilities of response (objective response rate \[ORR\], either partial or complete response) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria on each study regimen. (Phase II study) (24-FEB-2021) II. Estimate the frequency and severity of adverse events as classified and graded with Common Terminology Criteria for Adverse Events (CTCAE) in those patients who initiate their randomly assigned study treatment. (Phase II study) (03/19/2018) III. Estimate and compare ORR in each treatment group. (Phase III study) IV. Estimate the frequency and severity of adverse events in those patients who initiate their randomly assigned study treatment. (Phase III study) V. Estimate and compare mean patient reported outcome scores (PROs) as measured by National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) ovarian symptom index (NFOSI)-18 disease-related symptoms (DRS). (Phase III study) VI. Estimate and compare the treatment groups on the basis of the PROs: treatment side effects (TSE), function/well-being (FWB), fatigue (Functional Assessment of Chronic Illness Therapy \[FACIT\]-fatigue subscale) and abdominal discomfort (FACT/Gynecologic Oncology Group \[GOG\]-abdominal discomfort \[AD\] subscale). (Phase III study) (10/16/2017)
TRANSLATIONAL SCIENCE OBJECTIVES:
I. To determine whether biomarker levels in pre-treatment tissue, and pre- or on-treatment peripheral blood, and stool specimens are associated with ORR, PFS and/or overall survival (OS).
II. Estimate pre-treatment PD-L1 expression on tumor cells measured by quantitative immunohistochemistry (IHC), and determine whether it is associated with the duration of PFS or overall survival. (Integrated Biomarker) III. Analysis of T cell receptor (TCR) repertoires by deep sequencing of peripheral blood samples. (Exploratory Biomarkers \[10/16/2017\]) IV. Tumor "immunogenicity" as determined by the neo-antigen landscape and characterization of the tumor microenvironment using next-generation sequencing, including but not limited to whole exome sequencing and/or RNA sequencing. (Exploratory Biomarkers \[10/16/2017\]) V. Microbiome analysis via stool sampling. (Exploratory Biomarkers \[10/16/2017\]) VI. To determine whether changes in quantitative biomarker parameters after the first 6 and 12 weeks of therapy predict ORR, PFS and/or OS.
OUTLINE: Patients will be randomized to 1 of 3 arms.
ARM I: Patients receive pegylated liposomal doxorubicin hydrochloride intravenously (IV) over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15. (Closed to accrual as of February 09, 2021)
ARM II: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15. Patients also undergo computed tomography (CT) on study.
ARM III: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also undergo CT on study.
In all arms, cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 2 years, and then every 6 months for up to 3 years.
Status Flow
Change History
80 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE2/PHASE3 → None
-
Mar 2026 — May 2026 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Jan 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
▶ Show 75 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Oct 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Suspended → Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Suspended PHASE2_PHASE3
Status: Recruiting → Suspended
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Suspended → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Suspended PHASE2_PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Suspended PHASE2_PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Suspended PHASE2_PHASE3
-
May 2020 — Jun 2020 [monthly]
Suspended PHASE2_PHASE3
-
Apr 2020 — May 2020 [monthly]
Suspended PHASE2_PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Suspended PHASE2_PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Suspended PHASE2_PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Suspended PHASE2_PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Suspended PHASE2_PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Suspended PHASE2_PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Suspended PHASE2_PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Suspended PHASE2_PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Suspended PHASE2_PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Suspended PHASE2_PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Suspended PHASE2_PHASE3
Status: Recruiting → Suspended
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Suspended → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Suspended PHASE2_PHASE3
Status: Recruiting → Suspended
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2017 — Nov 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
Contact Information
- NRG Oncology
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .